BackCalidi Biotherapeutics Overview

Calidi Biotherapeutics Current Cash

Track Calidi Biotherapeutics's current cash ($6.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$6.63M
↓ 37.21% YoYΔ $-3.93M vs prior year quarter

Peer average

Loading

Calidi Biotherapeutics Current Cash History

Loading

Calidi Biotherapeutics vs. peers: Current Cash Comparison

Loading

Calidi Biotherapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Calidi Biotherapeutics (CLDI) FAQ

Calidi Biotherapeutics (CLDI) currently reports a current cash of $6.6M as of March 2026. That compares with $11M in the prior-year period — down 37.2% year over year. Use the charts on this page to explore Calidi Biotherapeutics's current cash history and peer comparisons.

Calidi Biotherapeutics's current cash decreased from $11M to $6.6M — a 37.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Calidi Biotherapeutics reported $6.6M in current cash as of March 2026. That compares with $11M in the prior-year period — down 37.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $6.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Calidi Biotherapeutics, and consider following CLDI for alerts when major investors trade the stock.